Future prospects in the treatment of erectile dysfunction: focus on avanafil
Serge Carrier, Amjad Alwaal, Al-Mannie
Research Article — Peer-Reviewed Source
Original research published by Carrier et al. in Drug Design Development and Therapy. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
The treatment of erectile dysfunction (ED) has been revolutionized in the last 15 years with the introduction of type 5 phosphodiesterase (PDE5) inhibitors. Their efficacy, safety, and ease of administration have made them first-line treatment for ED. This article reviews the current therapies available for ED, and the new PDE5 inhibitors that are being investigated. Furthermore, it examines all the current ED treatment options that are in different phases of development (including oral and topical pharmacotherapy, gene therapy, and tissue engineering). A special emphasis is on avanafil, a new PDE5 inhibitor that has been studied extensively in Phase I and II clinical trials and has undergone several Phase III trials. Avanafil is a promising medication for ED due to its favorable pharmacokinetics, safety, and efficacy.
Full text is available at the publisher.
Read at Publisher| DOI | 10.2147/dddt.s15852 |
| Journal | Drug Design Development and Therapy |
| Year | 2011 |
| Authors | Serge Carrier, Amjad Alwaal, Al-Mannie |
| License | Open Access — see publisher for license terms |
| Citations | 34 |